While Merck's oncology powerhouse Keytruda delivered another multibillion-dollar sales haul in the third quarter, regional ...

Merck reports Q3 sales of $16.7 billion, up 4% year-over-year, with Keytruda revenue rising 17%. EPS beats estimates; 2024 guidance updated on global demand shifts.

The CDC’s Advisory Committee on Immunization Practices is recommending that the age for pneumococcal vaccination be lowered to 50 years.

while Pneumovax 23 (pneumococcal vaccine polyvalent) vaccine sales declined 51% to $68 million. Sales of Vaxneuvance, Merck’s pneumococcal 15-valent conjugate vaccine, were $239 million ...

Merck’s ongoing pneumococcal vaccine development program is designed to provide options that address the specific needs of different populations, including infants and children, healthy adults ...

In June this year, the FDA approved Merck’s Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) to protect against 21 strains of bacteria to prevent a severe form of pneumococcal disease.

Vaccination with CAPVAXIVE may not protect all vaccine recipients. CAPVAXIVE is Merck’s approved 21-valent pneumococcal conjugate vaccine indicated for active immunization for the prevention of ...

CAPVAXIVE is Merck's approved 21-valent pneumococcal conjugate vaccine indicated for active immunization for the prevention of invasive disease and pneumonia in adults 18 years of age and older.

Merck (NYSE:MRK) announced Wednesday that its 21-valent pneumococcal vaccine, Capvaxive, approved in the U.S. to prevent pneumonia, generated positive immune responses in a Phase 3 trial for ...

In June this year, the FDA approved Merck’s Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) to protect against 21 strains of bacteria to prevent a severe form of pneumococcal disease. It’s the ...